EUSA Pharma acquires global rights to Arcoral Tab from Arcoral Pharma
The product, Arcoral Tab, which EUSA plans to rebrand under the Caphosol name, is a topical oral agent used in the treatment of conditions resulting in reduced salivary
Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular diseases.
TSC is a rare genetic condition characterized by formation of non-malignant tumors in several organs. The 16-week dose-ranging trial will evaluate Epidiolex against placebo in about 200 patients.